Episode 252: Today, Ann explains the Treasury’s decision to double its debt buybacks — and what could be driving the move. Then, we spin through market headlines, including earnings from Estée Lauder and Target, why Moderna stock is surging and robotics maker Unitree’s blockbuster IPO. Finally, we take a listener's question and dive into CRISPR Therapeutics to unpack why the biotech company behind the world’s first approved gene-editing therapy still isn’t profitable.Visit Schwab.com/FinancialDecoderwww.brewmarkets.com Subscribe to the Brew Markets newsletter: https://www.morningbrew.com/brew-mark...Follow Brew Markets on social:Instagram: instagram.com/brewmarketsTikTok: tiktok.com/@brewmarketsX: x.com/brewmarketsFollow Ann Berry on social:Instagram: instagram.com/annberry_nycX: x.com/AnnBerry_NYCListen to Brew Markets Here: swap.fm/l/9Qk4z73Z2nEwFiCB4qeeWatch Brew Markets Here:⁠ https://www.youtube.com/@BrewMarketsThe content shared on this podcast is for informational and entertainment purposes only and should not be considered financial, legal, or investment advice. Brew Markets, Morning Brew and their hosts are not licensed financial advisors. Listeners should conduct their own research and consult with qualified professionals before making any financial decisions or investments. The views expressed are those of the hosts and guests and do not necessarily reflect the views of Morning Brew or its affiliates. This podcast may include paid endorsements or sponsorshipsLearn more about your ad choices. Visit megaphone.fm/adchoices